Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Alvotech ( (ALVO) ).
On May 16, 2025, Alvotech announced the successful outcome of its offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm, which was oversubscribed and attracted over 3,000 new shareholders. The listing is expected to enhance Alvotech’s market presence in the Nordic and European regions, improve access to capital, and attract a broader investor base. Additionally, Alvotech has acquired Xbrane Biopharma’s R&D operations in Sweden, which will bolster its scientific capabilities and support its growth strategy.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s stock is rated moderately due to strong revenue growth and improved profitability offset by financial instability and cash flow concerns. Positive technical indicators and promising earnings guidance enhance the outlook, but valuation is moderate, and competitive pressures remain a risk.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines. The company aims to be a leader in the biosimilar space by offering high-quality, cost-effective products through a fully integrated approach. Alvotech has a diverse pipeline targeting various diseases and has formed strategic partnerships to expand its reach across multiple global markets.
Average Trading Volume: 164,525
Technical Sentiment Signal: Sell
Current Market Cap: $3.1B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.